Sensus Healthcare Director Eric Sachetta Ramps Up Shares in Bold Buy‑Low Play, Boosting Insider Confidence

Insider Buying Spree at Sensus Healthcare Signals Confidence

Sensus Healthcare has just posted a flurry of insider purchases, most notably from board director Eric Sachetta. On 24 August, Sachetta added 34,697 shares to his holdings, bringing his total to roughly 209,310 shares—an increase of about 30% in a single transaction. The purchase was made at $3.25 per share, well below the market price of $3.49 at the close on 23 August. This timing suggests that Sachetta is buying on a “buy‑on‑price‑drop” basis, capitalizing on the recent 13.48% monthly rally.

What It Means for Investors

Insider buying is generally a positive signal. Sachetta’s recent activity—three purchases in a two‑day span (24 August, 20 August, and 21 August)—demonstrates a pattern of incremental accumulation rather than a single large block trade. This incremental approach mitigates short‑term volatility for the stock while conveying a belief in the company’s long‑term prospects. Coupled with CEO Joseph Sardano’s recent purchase of 20,000 shares, the board’s collective ownership now sits above 1.4 million shares, representing a significant portion of the 54.98 million‑share market cap. For price‑action traders, these moves could precede a consolidation or breakout, especially as the stock has been trading near a 52‑week low of $2.66.

Sachetta’s Insider Profile

Over the past year, Sachetta has consistently added to his stake: 7,000 shares on 21 August, 24,000 on 20 August, 2,000 on 24 February, and 1,500 on 12 May. His purchases average around $3.30 per share, slightly below market, indicating a disciplined, value‑driven approach. He also maintains a 2,093‑share holding in a spouse’s name, suggesting a strategy to diversify ownership across family entities. The absence of any recent sales supports the view that he sees enduring upside in Sensus’s niche medical device portfolio.

Broader Insider Activity Context

While Sachetta’s buying spree is notable, it occurs against a backdrop of robust insider activity across the board. CEO Sardano’s purchase on 20 August increased his holdings to 1,220,293 shares, and other executives have made both buys and sells. The net effect is a high insider ownership density, which can align management incentives with shareholder value. However, the recent sale by CFO Javier Rampolla of 3,935 shares for $10.51 per share—above the current market—suggests that some insiders are still liquidating positions, perhaps to fund other opportunities.

Looking Ahead

Sensus Healthcare’s fundamentals—such as a negative P/E of –3.53 and a 52‑week high of $5.49—indicate that the market may still be undervaluing the company’s specialized radiation therapy products. With insider buying persisting, investors may want to monitor for a potential trend reversal, particularly if the company announces new product launches or regulatory approvals. In the meantime, the incremental purchases by Sachetta and other directors point to a bullish outlook that could translate into a steadier upward trajectory for the stock.